Search the Newsreel

What Do Boston Scientific (BSX) Recalls Mean For Device Safety And Clinical Use?

Boston Scientific (NYSE: BSX) has initiated multiple Class II product recalls for cardiac ablation generators and vascular access sheaths due to issues like labeling discrepancies and air embolism risks. These recalls affect devices crucial to electrophysiology and interventional oncology, raising questions about Boston Scientific's …

Noticias de acciones de Boston Scientific Corp (BSX)

Boston Scientific Corporation (NYSE:BSX) acaba de publicar sus resultados, y los analistas han fijado un precio objetivo de 62,69 dólares estadounidenses.

Die Boston Scientific Corporation (NYSE:BSX) hat soeben ihre Ergebnisse veröffentlicht, und Analysten haben ein Kursziel von 62,69 US-Dollar festgelegt.

Boston Scientific Corporation (NYSE:BSX) Just Reported, And Analysts Assigned A US$62.69 Price Target

Boston Scientific Corp (BSX) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

FMR LLC (NYSE: BSX) discloses 46.4M-share Boston Scientific stake in 13G/A

FMR LLC and Abigail P. Johnson have filed a Schedule 13G/A, disclosing beneficial ownership of 46,378,258.61 shares of Boston Scientific Corp (BSX) common stock, which represents a 3.1% stake as of June 30, 2026. FMR LLC holds sole voting power over 39,968,563.03 shares and …

Boston Scientific (BSX) Recalls Hundreds Of Thousands Of Devices As FDA Flags Software Issue

Boston Scientific (NYSE: BSX) director adds 1,182 shares in August stock purchases

Boston Scientific Corp (NYSE: BSX) director David C. Habiger reported open-market purchases of 1,182 common shares in early August 2026. These transactions occurred on August 3rd and 4th, with weighted average prices of $48

Bear of the Day: Boston Scientific (BSX)

Boston Scientific (BSX) manufactures medical devices and products used in various interventional medical specialties worldwide, including cardiovascular and surgical categories. On July 29, BSX reported revenue of $5.44 billion for their June quarter, up 7.5% over the same period last year. EPS came in …

AGS Launches its Award-Winning Table Game Progressive Platform, Bonus Spin Xtreme, Exclusively on BetRivers

LAS VEGAS, Aug. 05, 2026 (GLOBE NEWSWIRE) -- AGS, a global gaming supplier, recently debuted Bonus Spin Xtreme® (BSX) online, in an exclusive partnership with Rush Street Interactive, Inc. (NYSE: RSI) (“RSI”), a leading online casino and sports betting company in the United States …

Boston Scientific Corp. stock rises Tuesday, still underperforms market

Boston Scientific Corp. (BSX) stock increased by 1.36% on Tuesday, closing at $49.09. Despite this gain, the stock underperformed the broader market, as the S&P 500 Index (SPX) rose by 1.79% and the Dow Jones Industrial Average (DJIA) climbed by 1.71%. This marks the …

Tuesday 8/4 Insider Buying Report: BSX, CMCO

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. At Boston Scientific, a filing with the …

Will Belo Sun Mining Corp. (BSX) Beat Earnings Estimates in Its Next Report?

Boston Scientific (NYSE: BSX) director adds 5,000 shares in open-market buy

Edward J. Ludwig, a director at Boston Scientific Corp (NYSE: BSX), purchased 5,000 shares of common stock on July 31, 2026, at an average price of $45.4799 per share. This open-market transaction increased his direct holdings to 30,359 shares and was not executed under …

Boston Scientific (BSX) EVP boosts company stock stake through 401(k) rebalance

Joseph Michael Fitzgerald, EVP & Group President, Cardiology at Boston Scientific (BSX), acquired 64,198 shares of company common stock on July 31, 2026, through a 401(k) rebalance at $46.73 per share. This discretionary transaction increases his indirect holdings in the 401(k) to 64,198 shares, …

Boston Scientific 2Q 2026: Revenue $5.44B, EPS $0.61— 10-Q Summary

Boston Scientific (BSX) reported its second-quarter 2026 results, with revenue reaching $5.44 billion and diluted EPS of $0.61, marking increases of 7.5% and 15.1% respectively compared to the prior year. The growth was primarily driven by strong performance in Interventional Cardiology, Vascular Therapies, and …

[10-Q] BOSTON SCIENTIFIC CORP Quarterly Earnings Report

Boston Scientific (BSX) released its Q2 2026 Quarterly Earnings Report, detailing a 7.5% increase in reported net sales for the quarter and a 9.5% increase for the first six months of 2026, primarily driven by growth in its Interventional Cardiology, Vascular Therapies, and Electrophysiology …

Warum die Aktie von Boston Scientific (BSX) nach einem durchwachsenen zweiten Quartal, Rückrufmeldungen und einer Aktualisierung der Prognose um 5,6 % gestiegen ist

Por qué Boston Scientific (BSX) ha subido un 5,6 % tras unos resultados mixtos del segundo trimestre, noticias sobre una retirada de productos y la actualización de las previsiones

Ist Boston Scientific (BSX) Nach Den Zahlen Und Dem Gesenkten Ausblick Ein Schnäppchen?

BSX Q2 Deep Dive: WATCHMAN and Electrophysiology Challenges Temper Growth Outlook

BSX Q2 Deep Dive: WATCHMAN and Electrophysiology Challenges Temper Growth Outlook Medical device company Boston Scientific (NYSE:BSX) announced better-than-expected revenue in Q2 CY2026, with sales up 7.5% year on year to $5.44 billion. On the other hand, next quarter's revenue guidance of $5.27 billion …

Belo Sun Mining Corp. Revenue Breakdown – TSX:BSX

Belo Sun Mining Stock Price Forecast. Should You Buy BSX.TO?

What Boston Scientific’s Q2 Earnings Reveal About the EP Market’s New Competition

Boston Scientific Aktie unter Druck: Gesenkte Prognose und Analysten-Kritik belasten

Boston Scientific (BSX) Stock Ignores Margin Strength As Growth Outlook Softens

Blackstone Minerals (ASX:BSX): From Vietnamese Nickel to a Philippine Copper-Gold Pivot

The Beat: Boston Scientific plans $500M cuts, NatureWorks seeks CEO, Gravie expands focus

Boston Scientific is planning $500 million in cost reductions. NatureWorks, a bioplastics manufacturer backed by Cargill, is searching for a new CEO. Gravie, a company that provides health benefits, is increasing its hiring efforts to target a new type of customer.

Boston Scientific Lowered Full-Year Guidance on Headwinds in Electrophysiology, Watchman Portfolios, RBC Says

Boston Scientific (BSX) reported Q2 revenue and EPS that beat expectations but lowered its full-year PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …

BSX Q2 Earnings Call Highlights WATCHMAN and EP Pressure

Boston Scientific Corporation BSX delivered a solid second quarter, but management highlighted a tougher path ahead as pressure in WATCHMAN and electrophysiology changed the company's near-term outlook. Executives reduced full-year expectations while emphasizing cost actions and future product catalysts. The call focused on market …

Canaccord senkt Kursziel für Boston Scientific nach Prognoseanpassung

TD Cowen Adjusts Price Target on Boston Scientific to $56 From $61, Maintains Buy Rating

TD Cowen has revised its price target for Boston Scientific (NYSE:BSX) to $56, down from the previous $61, while reaffirming a Buy rating on the stock. This adjustment comes despite the retained positive outlook from the analyst firm.

A healthcare restructuring

Boston Scientific is initiating a three-year restructuring plan. This initiative will involve significant changes to its production processes and supply chain operations. The medical device maker aims to optimize its manufacturing and delivery systems.

What Are Wall Street Analysts' Target Price for Boston Scientific Stock?

Boston Scientific sign at manufacturer of medical devices Silicon Valley office By MichaelVi Marlborough, Massachusetts-based Boston Scientific Corporation (BSX) is a global medical technology company that develops, manufactures, and markets minimally invasive medical devices. With a market capitalization of approximately $68.5 billion, the company …

Mizuho cuts Boston Scientific stock price target on procedure declines

Mizuho lowered its price target for Boston Scientific (NYSE: BSX) to $60 from $70 due to declines in U.S. WATCHMAN stand-alone procedures and a revised electrophysiology outlook. Despite better-than-expected Q2 revenue, the company has cut its full-year organic top-line outlook twice, leading other firms …